Pfizer Limited (NSE:PFIZER) announced unaudited financial results for the quarter ended June 30, 2026, approved by its Board of Directors on July 28, 2026. The company reported consolidated net profit of Rs 204.47 crore, representing a year-on-year increase of 6.6%, while revenue from operations rose to Rs 653.17 crore, up 8.3% compared to the corresponding quarter ended June 30, 2025.
Key Highlights
- Net profit for Q1 FY27 stood at Rs 204.47 crore compared to Rs 191.75 crore in the corresponding quarter of the previous year, a YoY growth of 6.6%.
- Revenue from operations increased to Rs 653.17 crore in Q1 FY27 from Rs 603.05 crore in the corresponding quarter of FY26, representing YoY growth of 8.3%.
- Total income for the quarter, including other income, reached Rs 698.01 crore against Rs 670.22 crore in the corresponding prior-year quarter.
- Earnings per share (basic and diluted) for the quarter were Rs 4.47 per share compared to Rs 4.19 per share in the corresponding prior-year quarter.
- The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) and subject to limited review by statutory auditors BSR & Co. LLP, with no modifications reported.
- The company recognised exceptional items aggregating Rs 9.04 crore in Q1 FY27, relating to prior-period assessments under the New Labour Codes framework effective from November 21, 2025.
About the Company
Pfizer Limited (NSE:PFIZER, BSE Code: 500680) is a pharmaceutical company headquartered in Mumbai, operating in the Pharma & Healthcare sector. Incorporated in 1950 and listed on both NSE and BSE, the company manufactures and markets a diverse portfolio of branded pharmaceutical products across therapeutic areas. The company markets brands including Corex DX, Corex LS, Dolonex, and Neksium. In July 2025, Pfizer entered into an exclusive Supply and Marketing Agreement with Cipla Limited for the marketing and distribution of four brands, resulting in workforce restructuring in its field force and marketing teams during the financial year ended March 31, 2026.
Announcement in Detail
Pfizer Limited's Board of Directors, in a meeting held on July 28, 2026 commencing at 11:30 a.m. and concluding at 1:35 p.m., approved the unaudited financial results for the quarter ended June 30, 2026. The company disclosed a consolidated net profit of Rs 204.47 crore for Q1 FY27, up from Rs 191.75 crore in the same quarter of the previous financial year. Revenue from operations for the quarter reached Rs 653.17 crore, compared to Rs 603.05 crore in the corresponding period of FY26. Other income for the quarter amounted to Rs 44.84 crore, bringing total income to Rs 698.01 crore.
The profit before tax (including exceptional items) for Q1 FY27 was Rs 276.68 crore. The company recorded exceptional items of Rs 9.04 crore in the quarter under review. Total expenses for the quarter were Rs 421.33 crore. The company's paid-up equity share capital remains at Rs 45.75 crore with a face value of Rs 10 per share. The statutory auditors, BSR & Co. LLP, issued a limited review report on the unaudited results in accordance with Standard on Review Engagements (SRE) 2410, confirming that nothing in the review suggests the Statement does not comply with Ind AS 34 or disclosure requirements under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The exceptional items of Rs 9.04 crore recorded in Q1 FY27 relate to adjustments arising from the assessment of the new labour law framework. The Government of India had consolidated several existing labour laws into four labour Codes effective November 21, 2025. Based on the company's assessment and legal opinion, provisions for employee benefits were adjusted accordingly. The company noted that it continues to monitor developments pertaining to the New Labour Codes and will account for any further impact in accordance with applicable accounting standards.
Impact on Investors
The filing shows that Pfizer delivered positive year-on-year growth across key financial metrics. Revenue from operations grew 8.3% and net profit expanded 6.6%, indicating operational momentum in the pharmaceutical business despite the significant workforce restructuring undertaken during the prior financial year as part of the Cipla exclusive supply and marketing agreement. Investors will note that the company's profitability expanded even as it absorbed exceptional charges related to labour law compliance provisions. Earnings per share (basic and diluted) increased to Rs 4.47 per share from Rs 4.19 per share, reflecting the bottom-line growth trajectory.
The filing indicates that the company continues to face ongoing uncertainty around the implementation and financial impact of the New Labour Codes framework. The exceptional items charge of Rs 9.04 crore in Q1 FY27 represents a post-measure adjustment following the company's FY26 assessment, during which it had recognised an exceptional charge of Rs 49.16 crore for the full year. The disclosure that the company "continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards" signals potential for further adjustments in future quarters, creating a degree of earnings visibility uncertainty that investors should track in subsequent quarterly disclosures.
Sector / Market Context
The Indian pharmaceutical industry remains a significant global player, with the sector characterised by diverse therapeutic portfolios and regulatory compliance requirements. The introduction of the New Labour Codes framework by the Government of India represents a material shift in labour law compliance, consolidating multiple existing labour statutes into a unified structure effective November 21, 2025. This structural regulatory change has necessitated reassessment of employee benefit provisions across the industry, with many companies undertaking similar compliance exercises during FY26 and into FY27.
Pfizer's experience of personnel separation costs and employee benefit adjustments reflects broader sector-wide patterns as companies adapted to the new labour law regime. The company's ongoing restructuring of field force and marketing capabilities through the exclusive partnership with Cipla demonstrates competitive shifts within the pharmaceutical distribution and marketing market, where contractual outsourcing arrangements have become an alternative to direct-managed sales and marketing infrastructure. The company's ability to maintain revenue growth despite these organisational transitions indicates market demand for its core therapeutic portfolio, even as operating models evolve.